123,291 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD acquired a new stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 123,291 shares of the company's stock, valued at approximately $2,819,000. Price T Rowe Associates Inc. MD owned approximately 0.83% of Neurogene at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of Neurogene during the 3rd quarter worth $324,000. Barclays PLC raised its stake in shares of Neurogene by 319.4% during the 3rd quarter. Barclays PLC now owns 14,859 shares of the company's stock worth $623,000 after purchasing an additional 11,316 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Neurogene during the 4th quarter worth $72,000. Rhumbline Advisers raised its stake in shares of Neurogene by 9.2% during the 4th quarter. Rhumbline Advisers now owns 15,704 shares of the company's stock worth $359,000 after purchasing an additional 1,326 shares during the period. Finally, M&T Bank Corp bought a new stake in shares of Neurogene during the 4th quarter worth $323,000. 52.37% of the stock is currently owned by institutional investors.

Neurogene Trading Down 2.7%

NGNE stock traded down $0.40 during midday trading on Friday, hitting $14.60. The company had a trading volume of 173,021 shares, compared to its average volume of 236,868. The stock has a market cap of $208.23 million, a price-to-earnings ratio of -3.36 and a beta of 1.56. The stock's 50 day moving average price is $13.48 and its 200 day moving average price is $21.30. Neurogene Inc. has a 52 week low of $6.88 and a 52 week high of $74.49.

Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.03). Analysts predict that Neurogene Inc. will post -4.27 earnings per share for the current year.

Insider Activity

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares of the company's stock, valued at approximately $1,225,490.42. This represents a 5.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.64% of the company's stock.

Wall Street Analysts Forecast Growth

NGNE has been the subject of several recent research reports. William Blair reissued an "outperform" rating on shares of Neurogene in a report on Tuesday, March 25th. BMO Capital Markets decreased their price objective on Neurogene from $45.00 to $16.00 and set an "outperform" rating for the company in a report on Monday, April 14th. HC Wainwright decreased their price objective on Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. Finally, Robert W. Baird set a $38.00 price objective on Neurogene in a report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $47.20.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.